Physician profile
Ryan Whinery
NPI 1417465568
$4,621.40
in general payments reported to CMS, 2019-2025
18 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $218 · 2021: $190 · 2022: $910 · 2023: $835 · 2024: $802 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,795 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,794.53 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,705.26 | 2019-2025 | Precision 1, Tryptyr, Total30 |
| Bausch & Lomb Americas INC. | $362.22 | 2023-2025 | Xiidra, Miebo, Infuse |
| Johnson & Johnson Vision Care, INC. | $350.45 | 2019-2025 | |
| Biotissue Holdings INC. | $313.53 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $262.15 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $256.92 | 2022-2023 | Oxervate |
| Sight Sciences, INC. | $197.58 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $191.32 | 2021-2023 | |
| Oyster Point Pharma, INC. | $167.32 | 2022-2025 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $162.32 | 2023-2025 | Clariti Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Amgen INC. | $149.04 | 2024 | Tepezza |
| Genzyme Corporation | $117.68 | 2019 | |
| Horizon Therapeutics Plc | $116.64 | 2023 | Tepezza |
| Allergan, INC. | $109.94 | 2020 | |
| Abbvie INC. | $69.05 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $36.35 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.20 | 2019 | |
| Kala Pharmaceuticals, INC. | $21.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Whinery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.